Rank #1666TVTX

Travere Therapeutics, Inc.

$29.30

5.13% (Daily)

Market Cap

$2.62B

Revenue

$435.83M

Rank by MCap

#1666

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Eric M. Dube Ph.D.

Headquarters

San Diego, CA

Employees

385

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport...